Literature DB >> 28576176

Controversies in Postoperative Irradiation of Oropharyngeal Cancer After Transoral Surgery.

Sue S Yom1, Jon Mallen-St Clair2, Patrick K Ha2.   

Abstract

Transoral surgery (TOS) is a novel technology whose adoption is expanding in the United States and other countries. TOS offers the possibility of a minimally invasive surgical approach to head and neck cancers. Its most frequent application has been in oropharyngeal cancers (OPC), of which most are associated with human papillomavirus (HPV). For HPV-associated OPC, where high response and survival rates are expected, deintensification of standard therapy is a major area of clinical research. In HPV-OPC, traditional pathologic risk factors indicating a need for adjuvant radiation or chemoradiation may not apply as strongly.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Human papillomavirus; Oropharyngeal cancer; Radiation; Transoral laser microscopy; Transoral robotic surgery

Mesh:

Year:  2017        PMID: 28576176     DOI: 10.1016/j.soc.2017.01.006

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  4 in total

1.  Prognostic nomograms based on immune scores for head-neck squamous cell carcinoma patients.

Authors:  Wenfei Li; Kun Zhao; Zhanqiu Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-10-17       Impact factor: 2.503

Review 2.  Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.

Authors:  B R Heath; N L Michmerhuizen; C R Donnelly; K Sansanaphongpricha; D Sun; J C Brenner; Y L Lei
Journal:  J Dent Res       Date:  2019-07-24       Impact factor: 6.116

Review 3.  Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

Authors:  Y S Tan; K Sansanaphongpricha; M E P Prince; D Sun; G T Wolf; Y L Lei
Journal:  J Dent Res       Date:  2018-03-13       Impact factor: 6.116

4.  Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.

Authors:  Yee Sun Tan; Kanokwan Sansanaphongpricha; Yuying Xie; Christopher R Donnelly; Xiaobo Luo; Blake R Heath; Xinyi Zhao; Emily Bellile; Hongxiang Hu; Hongwei Chen; Peter J Polverini; Qianming Chen; Simon Young; Thomas E Carey; Jacques E Nör; Robert L Ferris; Gregory T Wolf; Duxin Sun; Yu L Lei
Journal:  Clin Cancer Res       Date:  2018-05-16       Impact factor: 13.801

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.